NIH’s NIAID initiating dose evaluation studies in animal models of Pluristem’s PLX-R18 in the treatment of acute radiation syndrome

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, has announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. Aid / Disasters News From Medical News Today BEST DEAL UPDATE: SPECIAL … Read more…